U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07490613) titled 'A Phase I Study of SHR-3836 in Patients With Multiple Myeloma' on March 18.
Brief Summary: This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: SHR-3836 administered as multiple doses.
* In the dose escalation phase, doses are escalated sequentially from low to high levels.
* In the dose expansion phase, one or more selected dose levels are further evaluated.
Recrui...